PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY

Corvus Pharmaceuticals presents data on ciforadenant's potential to overcome anti-PD1 resistance in mCRPC at SITC 39th Annual Meeting. Studies reveal SPP1+ myeloid cells as critical mediators of immunotherapy resistance, with ciforadenant reducing immunosuppression and enhancing anti-PD1 sensitivity in a murine model. The adenosine gene signature, reflecting adenosine-induced immunosuppression, was elevated in SPP1+ macrophages, supporting ciforadenant's role in shifting to a less immunosuppressive myeloid environment.

Corvus Pharmaceuticals presents data on ciforadenant's potential to overcome anti-PD1 resistance in mCRPC, identifying SPP1+ myeloid cells and adenosine signaling as key mechanisms. The study, led by Dr. Lawrence Fong, showed ciforadenant's efficacy in reducing immunosuppression and enhancing anti-PD1 therapy sensitivity in a murine model, consistent with clinical trial data.

Engineered nonpathogenic E. coli displaying decoy-resistant IL18 show potent anti-tumor responses, boosting CAR-NK cell therapy and demonstrating safety in hard-to-treat tumors.

Engineered nonpathogenic E. coli expressing immune-activating cytokines on their surfaces demonstrated potent anti-tumor responses and enhanced CAR-NK cell therapy efficacy, with a 50-60% cure rate in mice, suggesting potential as a 'tumor GPS' for NK cells.

Nomic and PICI collaborate to profile ~3000 blood samples from RADIOHEAD study using nELISA™ to understand immunotherapy responses, aiming to improve patient care through precision medicine.

Adding novel agents to perioperative durvalumab for NSCLC led to higher pCR and mPR rates compared to historical rates with durvalumab and chemotherapy. The highest response rates occurred with the addition of Dato-DXd (pCR 34.1%, mPR 65.9%). All combinations demonstrated manageable safety profiles and surgical rates comparable to approved regimens.

Arsenal Biosciences raised $325M in Series C to advance CAR T-cell therapies for solid tumors, with AB-1015 for ovarian cancer and AB-2100 for kidney cancer in early clinical development.